GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (NAS:MOR) » Definitions » 5-Year Yield-on-Cost %

MorphoSys AG (MorphoSys AG) 5-Year Yield-on-Cost % : 0.00 (As of May. 03, 2024)


View and export this data going back to 2018. Start your Free Trial

What is MorphoSys AG 5-Year Yield-on-Cost %?

MorphoSys AG's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for MorphoSys AG's 5-Year Yield-on-Cost % or its related term are showing as below:



MOR's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.88
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of MorphoSys AG's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, MorphoSys AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's 5-Year Yield-on-Cost % falls into.



MorphoSys AG 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of MorphoSys AG is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

MorphoSys AG  (NAS:MOR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


MorphoSys AG 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (MorphoSys AG) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

MorphoSys AG (MorphoSys AG) Headlines

From GuruFocus

MorphoSys AG Reports First Quarter 2023 Financial Results

By Business Wire Business Wire 05-03-2023